Acute Myeloid Leukemia with NPM1 Mutation

Acute Myeloid Leukemia with NPM1 Mutation — Trials · CancerIndex

Clinical trials

Registered studies

6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 4
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Kura Oncology, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–6 of 6 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07566585	Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation	withdrawn	Phase 1	0	BlueSphere Bio, IncINDUSTRY	1	Sep 10, 2026	clinicaltrials
NCT05886049	A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease	recruiting	Phase 1	38	National Cancer Institute (NCI)NIH	1